ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för odanacatib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

14 träffar

Bibliografisk träff 2024-07-11

Novel selective proline-based peptidomimetics for human cathepsin K inhibition.

Cardoso Prado Martins F, Dos Reis Rocho F, Bonatto V, Jatai Batista PH, Lameira J, Leitão A, Montanari CA.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2024.129887

Bibliografisk träff 2023-11-11

Identification of Ebselen derivatives as novel SARS-CoV-2 main protease inhibitors: Design, synthesis, biological evaluation, and structure-activity relationships exploration.

Zhang H, Li J, Toth K, Tollefson AE, Jing L, Gao S, Liu X, Zhan P.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2023.117531

Bibliografisk träff 2022-10-09

Discovery of selective covalent cathepsin K inhibitors containing novel 4-cyanopyrimidine warhead based on quantum chemical calculations and binding mode analysis.

Jia Y, Wang K, Wang H, Zhang B, Yang K, Zhang Z, Dong H, Wang J.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2022.117053

Bibliografisk träff 2019-08-28

Synthesis and structure-activity relationship of nitrile-based cruzain inhibitors incorporating a trifluoroethylamine-based P2 amide replacement.

Gomes JC, Cianni L, Ribeiro J, Dos Reis Rocho F, da Costa Martins Silva S, Batista PHJ, Moraes CB, Franco CH, Freitas-Junior LHG, Kenny PW, Leitão A, Burtoloso ACB, de Vita D, Montanari CA.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.115083

Bibliografisk träff 2019-02-02

Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.

Yuan XY, Ren Z, Wu Y, Bougault C, Brizuela L, Magne D, Buchet R, Mebarek S.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.02.003

Bibliografisk träff 2018-08-31

Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors.

Rocha DA, Silva EB, Fortes IS, Lopes MS, Ferreira RS, Andrade SF.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2018.08.079

Bibliografisk träff 2017-12-07

Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S.

Galibert M, Wartenberg M, Lecaille F, Saidi A, Mavel S, Joulin-Giet A, Korkmaz B, Brömme D, Aucagne V, Delmas AF, Lalmanach G.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2017.12.012

Bibliografisk träff 2012-10-11

Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.

Crawford JJ, Kenny PW, Bowyer J, Cook CR, Finlayson JE, Heyes C, Highton AJ, Hudson JA, Jestel A, Krapp S, Martin S, Macfaul PA, McDermott BP, McGuire TM, Morley AD, Morris JJ, Page KM, Ribeiro LR, Sawney H, Steinbacher S, Smith C, Dossetter AG.

J Med Chem · journal article · DOI 10.1021/jm301119s

Bibliografisk träff 2012-07-10

(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.

Dossetter AG, Beeley H, Bowyer J, Cook CR, Crawford JJ, Finlayson JE, Heron NM, Heyes C, Highton AJ, Hudson JA, Jestel A, Kenny PW, Krapp S, Martin S, MacFaul PA, McGuire TM, Gutierrez PM, Morley AD, Morris JJ, Page KM, Ribeiro LR, Sawney H, Steinbacher S, Smith C, Vickers M.

J Med Chem · journal article · DOI 10.1021/jm3007257

Bibliografisk träff 2010-12-19

Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.

Isabel E, Mellon C, Boyd MJ, Chauret N, Deschênes D, Desmarais S, Falgueyret JP, Gauthier JY, Khougaz K, Lau CK, Léger S, Levorse DA, Li CS, Massé F, Percival MD, Roy B, Scheigetz J, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2010.12.070

Bibliografisk träff 2010-06-01

Emerging targets in osteoporosis disease modification.

Allen JG, Fotsch C, Babij P.

J Med Chem · review; journal article · DOI 10.1021/jm9018756

Bibliografisk träff 2009-12-28

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.

Isabel E, Bateman KP, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Gauthier JY, Lamontagne S, Lau CK, Léger S, LeRiche T, Lévesque JF, Li CS, Massé F, McKay DJ, Mellon C, Nicoll-Griffith DA, Oballa RM, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett · comparative study; journal article · DOI 10.1016/j.bmcl.2009.12.083

Bibliografisk träff 2008-12-24

Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.

Boyd MJ, Crane SN, Robichaud J, Scheigetz J, Black WC, Chauret N, Wang Q, Massé F, Oballa RM.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2008.12.053

Bibliografisk träff 2008-01-15

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2007.12.047